Why Vicor Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 23 2025
0mins
Source: Benzinga
Vicor Corporation Earnings Report: Vicor's shares surged 39% in pre-market trading after reporting second-quarter earnings of 91 cents per share, significantly exceeding analyst expectations of 18 cents, along with sales of $141.046 million against a forecast of $96.433 million.
Pre-Market Stock Movements: Several stocks experienced notable changes in pre-market trading, including ABIVAX which rose 410%, while Texas Instruments and VisionWave Holdings saw declines of 12% and 13%, respectively.
Analyst Views on PMN
Wall Street analysts forecast PMN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PMN is 8.67 USD with a low forecast of 3.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.154
Low
3.00
Averages
8.67
High
18.00
Current: 8.154
Low
3.00
Averages
8.67
High
18.00
About PMN
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
